Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Reports Preliminary Q1 Revenues of $549M to $554M, Beating Analyst Expectations

NEW YORK – Bruker announced after the close of the market on Tuesday that it anticipates Q1 2021 revenues of $549 million to $554 million, which would represent year-over-year growth of approximately 30 percent to 31 percent.

On average, analysts are expecting Q1 revenues of $506.9 million.

The company said the performance was driven by double-digit organic year-over-year revenue growth across all three of its Bruker Scientific Instrument groups, including the placement of two GHz-class NMR systems.

Bruker estimated non-GAAP organic revenue growth of 22 percent to 23 percent for Q1 2021, up from its previous projection of greater than 15 percent organic growth for the quarter.

In Wednesday morning trading on Nasdaq, Bruker shares were up a fraction of a percent to $69.14.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.